News and Trends 20 Sep 2017 Once-a-Day Inhaler Approved for Treatment of Deadly Lung Disease in the US A British-American collaboration’s once-daily triple therapy inhaler has been approved for use by appropriate COPD patients in the US. A new triple therapy inhaler for chronic obstructive pulmonary disease (COPD), Trelegy Ellipta, has been developed by British giant GSK in collaboration with Innoviva in the US. The inhaler is targeted at patients who are struggling with airflow […] September 20, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Sponsored 20 Sep 2017 What you need to Know about the Legalization of Cannabis for Medical Use It is mentioned in song texts, studied in scientific papers, listed on political agendas: Cannabis. The global discussion has been raging for decades. Should a drug that is listed as a strong narcotic in many countries be legalized for medicinal or recreational use? In recent years, several countries, including Canada, Italy and the Czech Republic […] September 20, 2017 - 8 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Interview 20 Sep 2017 A Peek Inside Europe’s Best Incubator: A Conversation with Babraham’s Chief Executive Derek Jones is at the helm of Babraham Bioscience Technologies. I caught up with him to talk about strategies for biotech startups. Confusion is common when it comes to navigating the various organizing entities of Babraham, a life science campus just a few kilometers southeast of Cambridge. It’s famously home to a number of standout […] September 20, 2017 - 9 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
More News! 19 Sep 2017 Scottish Scientists Claim that the Genome Controls the Aging of the Brain Scientists in Scotland claim gene expression in the brain is so precisely controlled that they could predict your age just by looking at your genome. Researchers at the University of Edinburgh believe that genes in the brain are expressed at very specific times during a person’s life to carry out particular functions. Changes were seen […] September 19, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 18 Sep 2017 British Unicorn Gets $40M Boost from Bill & Melinda Gates Foundation The Bill & Melinda Gates Foundation have injected $40M (€33M) into Immunocore to accelerate the development of its immunotherapies for infectious diseases. Investment from the Bill & Melinda Gates Foundation will support the development of Immunocore’s ImmTAV and ImmTAB TCR-based technologies, which help the immune system to target virally and bacterially infected cells, respectively. In particular, […] September 18, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
More News! 18 Sep 2017 Austrian Biotech Scores a Phase III Win in the Fight Against Antibiotic Resistance The novel antibiotic lefamulin brought home late-stage success to Nabriva by proving itself to be on par with the standard treatment in pneumonia. Novartis spinout Nabriva has been developing antibiotics since 2006 and now boasts over 150 employees and a $285M (€239M) market cap. The company just reported that its latest stage program, centered on lefamulin for […] September 18, 2017 - 1 minutemin - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 18 Sep 2017 German Humira Biosimilar for Inflammatory Diseases Cleared for EMA Approval Cyltezo, an adalimumab biosimilar drug by Boehringer Ingelheim, has received the backing to be marketed in Europe. The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended Cyltezo for approval, moving it closer to the market and offering a new treatment for a range of inflammatory diseases. The biosimilar drug of adalimumab (Humira) could treat […] September 18, 2017 - 1 minutemin - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 18 Sep 2017 British Rapid Action Allergy Vaccine Gets Approval for Phase II Trial Allergy Therapeutics’ vaccine against hayfever has received approval to begin a trial to determine its optimal dose. Allergy Therapeutics will begin a Phase II trial of its PQ Grass vaccine for grass pollen-induced allergic rhinitis imminently. A major selling point for PQ Grass is its ultra-short course, which reduces treatment time from 1 year to […] September 18, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 18 Sep 2017 Update: After 25 years, MorphoSys Gets its First Antibody Approved Update (19/09/2017): Janssen has received a positive CHMP opinion recommending the approval of Tremfya (guselkumab) in Europe for moderate to severe plaque psoriasis. The approval could make Tremfya the first antibody developed by MorphoSys to hit the European market, just a few months after its US approval. Originally published on 14/07/2017 Janssen has received FDA approval for Tremfya […] September 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Inside Labiotech 18 Sep 2017 Press Release: We raised our second financing round to become the largest biotech media 🚀 Happy news to announce this morning: we just closed our second fundraising from new and existing investors 😉👌 It’s a major milestone for the development of Labiotech.eu as it will allow us to continue investing in amazing content, launch new products and grow our revenues. Thanks to the team for their amazing work and for making […] September 18, 2017 - 3 minutesmins - By Philip Hemme Share WhatsApp Twitter Linkedin Email
Interview 18 Sep 2017 David Chiswell: “We are getting close to the best way of making antibodies” We interviewed David Chiswell, a pioneer in the development of therapeutic antibodies and now the CEO of Kymab, which he has the ambition to turn into the “European Genentech.” David Chiswell was, along with Greg Winter, one of the co-founders of Cambridge Antibody Technology. “We both wanted to start an antibody company,” says Chiswell. “And […] September 18, 2017 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 16 Sep 2017 How Does it Feel Like to be a Slime Mold in Berlin? Bioartist Heather Barnett explores the amusing world of a microorganism that can navigate its way around cities much like a human would do. Physarum polycephalum, commonly known as slime mold, is a fascinating microorganism. This yellow single-celled being has no brain or nervous system, but it can play piano and write Hebrew. It can also […] September 16, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email